Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner
Executive Summary
Takeda's $50m+ deal for Enterome's EB8018 is based on a separate platform from that being used under the French company's collaboration with Johnson & Johnson.
You may also be interested in...
France’s Enterome Eyes Merger To Make NASDAQ Move
CEO Pierre Belichard tells Scrip that the French biotech has enough cash and assets to prosper alone but it is also weighing up a reverse merger that would give Enterome a listing on the NASDAQ.
Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna
Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.